CRB licenses biodrug delivery protein screening tech

By Gareth Macdonald

- Last updated on GMT

CRB licneses cell penetration delivery screening tech
CRB licneses cell penetration delivery screening tech

Related tags Protein

Cambridge Research Biochemicals (CRB) has licensed rights to a system that – it claims – will let biopharmas identify the best delivery peptides more quickly.

The technology – which was developed by scientists at the UK Medical Research Council’s Laboratory of Molecular Biology (MRC-LMB) – allows CRB to combine a biopharmas customers’ biomolecule with many different cell penetration peptides simultaneously to accelerate the selection process as spokesman Laurent Caron explained.

There isn’t a universally successful carrier and often researchers have to select one that works for a particular cargo and a particular cell type. We offer researchers a screening tool to identify successful carriers for their application saving them time and money​.”

He told that screening is necessary because while a lot of research has been done the mechanism by which peptide enter cells is poorly understood, making it difficult to identify the molecule with the best characteristics for drug delivery.

There are unresolved questions regarding the uptake mechanism of cell penetrating peptides and different pathways have been suggested. Direct penetration is a possible explanation, the carrier CPP forming a pore or a micelle by interaction with the cell membrane.”

UK-headquartered CRB plans to begin offering the technology as a contract service to scientists working in academia and at biotech and pharmaceutical companies for research purposes from October as commercial director Emily Humphrys explained.

"We are really pleased to be able to provide a long-awaited service for the selection of the most appropriate cell-penetrating peptide for delivery of drugs to both academic researchers and industry

Mike Gait, from the MRC, was similarly upbeat, adding that: "We are very excited that CRB has taken on our new method and will open it up to a wider number of researchers and to industry, ultimately enabling the development of new treatments."

Related topics Bio Developments Bio-Outsourcing

Related news

Show more

Related products

show more

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Content provided by Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Related suppliers

Follow us


View more